Repligen Corporation

Equities

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
183.9 USD -0.45% Intraday chart for Repligen Corporation -7.92% +2.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM
Repligen Corporation Appoints Maggie A. Pax as Board of Directors CI
Repligen Insider Sold Shares Worth $681,348, According to a Recent SEC Filing MT
Repligen Insider Sold Shares Worth $3,298,632, According to a Recent SEC Filing MT
Repligen Insider Sold Shares Worth $866,204, According to a Recent SEC Filing MT
UBS Adjusts Repligen Price Target to $225 From $211, Maintains Buy Rating MT
Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating MT
RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating MT
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday MT
Sector Update: Health Care MT
Transcript : Repligen Corporation, Q4 2023 Earnings Call, Feb 21, 2024
Repligen Q4 Adjusted Earnings, Revenue Decline; Issues 2024 Guidance; Shares Fall Premarket MT
Sartorius falls - outlook from Repligen disappointed DP
(RGEN) REPLIGEN CORPORATION Expects Fiscal Year 2024 EPS Range $1.42 - $1.49 MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 Revenue $155.7M, vs. Street Est of $156.3M MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 EPS $0.33, vs. Street Est of $0.34 MT
Repligen Corporation Provides Earnings Guidance for the Year 2024 CI
Repligen Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Repligen Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Stocks Decline Pre-Bell as Fed Outlook, Rates Weigh; Asia Mixed, Europe Mostly Up MT
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Repligen Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 02:15 PM
Deutsche Bank Adjusts Repligen Price Target to $175 From $150, Maintains Hold Rating MT
UBS Adjusts Repligen Price Target to $211 From $170, Maintains Buy Rating MT
Repligen Corporation announced that it has received $290.1 million in funding CI
Chart Repligen Corporation
More charts
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
183.9 USD
Average target price
211.3 USD
Spread / Average Target
+14.88%
Consensus